CLINICAL_TRIALS
trial_result
· 2024-01-26
Clinical Trial Update: A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) [Phase 2]
Summary
Phase 2 study of SP-02L in relapsed or refractory Peripheral T-cell Lymphoma has completed; results posted in 2024.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Solasia Pharma K.K. | Conditions: Peripheral T-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-01-26